HHS’ oversight policy, developed in 2017, requires funding agencies to refer proposed research “reasonably anticipated” to create or involve high-risk pathogens to the department for an additional analysis of risks and benefits. However, the GAO found the framework for such reviews “allows for subjective and potentially inconsistent interpretations,” which leaves HHS “without assurance the department is reviewing all necessary research proposals.”
The office recommended HHS develop a clear standard of what “reasonably anticipated” means to ensure consistency in reviewing high-risk research, among other recommendations.
View the full report here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.